Biotech Small-Cap Approvals — May 14, 2026

NME designation grants 5-year data exclusivity as the highest commercial signal; bullish with top-tier 8/10 strength and materiality despite NOT_DISCLOSED peak sales.

Label expansion enhances combo therapy market access in HIV; bullish signal at 5/10 strength and materiality.

Biosimilar approvals for LEVETIRACETAM (MYLAN LABS LTD), HYDROCORTISONE SODIUM SUCCINATE (ZYDUS PHARMS), PALIPERIDONE (I3 PHARMS), BRIMONIDINE TARTRATE (MICRO LABS), and Unknown (DR REDDYS LABS LTD) signal bearish revenue erosion (30-60% over 2-3 years) for originators.

ACCORD BIOPHARMA INC. gains entry via PEGFILGRASTIM-PCCG (ENNUMO) NME in oncology supportive care.

LACHMAN CONSULTANT SERVICES, INC. expands DOLUTEGRAVIR combo (with LAMIVUDINE and TENOFOVIR DISOPROXIL FUMARATE) for broader HIV adoption.

MYLAN LABS LTD, ZYDUS PHARMS, I3 PHARMS, MICRO LABS, and DR REDDYS LABS LTD enter via biosimilars in neurology, psych, ophth, and other.

Five biosimilar approvals (LEVETIRACETAM, HYDROCORTISONE SODIUM SUCCINATE, PALIPERIDONE, BRIMONIDINE TARTRATE, Unknown) to small-cap sponsors signal accelerated generics/biosimilars momentum.

{"entity"=>"ACCORD BIOPHARMA INC.", "reason"=>"NME approval for PEGFILGRASTIM-PCCG (ENNUMO) with high 8/10 bullish signal requires launch tracking.", "trigger"=>"commercial launch date, initial uptake data"}

{"entity"=>"LACHMAN CONSULTANT SERVICES, INC.", "reason"=>"Label expansion for DOLUTEGRAVIR combo signals HIV portfolio growth.", "trigger"=>"market share data, payer coverage decisions"}

{"entity"=>"MYLAN LABS LTD, ZYDUS PHARMS, I3 PHARMS, MICRO LABS, DR REDDYS LABS LTD", "reason"=>"Biosimilar approvals in multiple TAs highlight competitive entry dynamics.", "trigger"=>"biosimilar pricing, originator erosion metrics"}